Disease Domain | Count |
---|---|
Infectious Diseases | 5 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 5 |
Vaccine | 1 |
Conjugated vaccine | 1 |
Genetically engineered subunit vaccine | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date31 Dec 2019 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date01 Dec 2011 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date20 Feb 2024 |
Sponsor / Collaborator Xiamen University [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Human papillomavirus 16/18 vaccine recombinant bivalent(Xiamen Innovax) | Uterine Cervical Cancer More | Approved |
Hepatitis E vaccine recombinant(Xiamen Innovax Biotech Co. Ltd.) | Hepatitis E More | Approved |
9-Valent HPV Vaccine(Xiamen Innovax) | Human Papillomavirus Infection More | NDA/BLA |
20-valent neumococcal polysaccharide conjugate vaccine (Xiamen Innovax) | Pneumococcal Infections More | Phase 1 |
Rotavirus vaccine (Xiamen Innovax Biotech) | Rotavirus Infections More | Preclinical |